Bibliography for MD7511 Injectable Therapies BETA

[1]

A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes: http://link.springer.com.ezproxy4.lib.le.ac.uk/article/10.1007/s00125-007-0911-x/fulltext.html.

[2]

Akram, J. et al. 1999. Insulin lispro (Lys(B28), Pro(B29)) in the treatment of diabetes during the fasting month of Ramadan. Diabetic Medicine. 16, 10 (Oct. 1999), 867–874. DOI:https://doi.org/10.1046/j.1464-5491.1999.00164.x.

[3]

Aldam, P. et al. 2014. Perioperative management of diabetic patients: new controversies. British Journal of Anaesthesia. 113, 6 (Dec. 2014), 906–909. DOI:https://doi.org/10.1093/bja/aeu259.

[4]

Ali, S. et al. 2016. Guidelines for managing diabetes in Ramadan. Diabetic Medicine. 33, 10 (Oct. 2016), 1315–1329. DOI:https://doi.org/10.1111/dme.13080.

[5]

Anderson, B. et al. 2005. The art of empowerment: stories and strategies for diabetes educators. American Diabetes Association.

[6]

Anderson, J.W. et al. 2003. Importance of Weight Management in Type 2 Diabetes: Review with Meta-analysis of Clinical Studies. Journal of the American College of Nutrition. 22, 5 (Oct. 2003), 331–339. DOI:https://doi.org/10.1080/07315724.2003.10719316.

[7]

Ashwell, S.G. et al. 2006. Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetes. Diabetic Medicine. 23, 3 (Mar. 2006), 285–292. DOI:https://doi.org/10.1111/j.1464-5491.2005.01781.x.

[8]

Bailey, S. 2011. Academic writing: a handbook for international students. Routledge.

[9]

Bajwa, S. et al. 2015. Interdisciplinary position statement on management of hyperglycemia in peri-operative and intensive care. Journal of Anaesthesiology Clinical Pharmacology. 31, 2 (2015). DOI:https://doi.org/10.4103/0970-9185.155141.

[10]

Bakiner, O. et al. 2009. Repaglinide plus single-dose insulin glargine: a safe regimen for low-risk type 2 diabetic patients who insist on fasting in Ramadan. Acta Diabetologica. 46, 1 (Mar. 2009), 63–65. DOI:https://doi.org/10.1007/s00592-008-0062-7.

[11]

Barker, P. et al. 2015. Peri-operative management of the surgical patient with diabetes 2015. Anaesthesia. 70, 12 (Dec. 2015), 1427–1440. DOI:https://doi.org/10.1111/anae.13233.

[12]

Benkhadra, K. et al. 2016. Real Time Continuous Glucose Monitoring in type 1 diabetes: A Systematic review and Individual Patient Data Meta-Analysis. Clinical Endocrinology. (Dec. 2016). DOI:https://doi.org/10.1111/cen.13290.

[13]

Bergenstal, R.M. et al. 2012. A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin-Treated Patients With Type 2 Diabetes. Diabetes Care. 35, 11 (Nov. 2012), 2140–2147. DOI:https://doi.org/10.2337/dc12-0060.

[14]

Bergenstal, R.M. et al. 2008. Adjust to Target in Type 2 Diabetes: Comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine. Diabetes Care. 31, 7 (Jul. 2008), 1305–1310. DOI:https://doi.org/10.2337/dc07-2137.

[15]

Bergenstal, R.M. et al. 2010. Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes. New England Journal of Medicine. 363, 4 (Jul. 2010), 311–320. DOI:https://doi.org/10.1056/NEJMoa1002853.

[16]

Bretzel, R.G. et al. 2008. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. The Lancet. 371, 9618 (Mar. 2008), 1073–1084. DOI:https://doi.org/10.1016/S0140-6736(08)60485-7.

[17]

Burnett, J.C.D. 2006. Long‐ and Short‐Haul Travel by Air: Issues for People With Diabetes on Insulin. Journal of Travel Medicine. 13, 5 (Sep. 2006), 255–260. DOI:https://doi.org/10.1111/j.1708-8305.2006.00057.x.

[18]

Buse, J.B. et al. 2014. Contribution of Liraglutide in the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira). Diabetes Care. 37, 11 (Nov. 2014), 2926–2933. DOI:https://doi.org/10.2337/dc14-0785.

[19]

Buse, J.B. et al. 2011. Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes. Annals of Internal Medicine. 154, 2 (Jan. 2011). DOI:https://doi.org/10.7326/0003-4819-154-2-201101180-00300.

[20]

Crasto, W. 2016. Handbook of Insulin Therapies. Adis; 1st ed. 2016 edition.

[21]

Crasto, W. 2016. Handbook of Insulin Therapies. Adis; 1st ed. 2016 edition.

[22]

Crasto, W. 2016. Handbook of Insulin Therapies. Adis; 1st ed. 2016 edition.

[23]

Crasto, W. 2016. Handbook of Insulin Therapies. Adis; 1st ed. 2016 edition.

[24]

Crasto, W. 2016. Handbook of Insulin Therapies. Adis; 1st ed. 2016 edition.

[25]

Crasto, W. 2016. Handbook of Insulin Therapies. Adis; 1st ed. 2016 edition.

[26]

Crasto, W. et al. 2009. Insulin U-500 in severe insulin resistance in type 2 diabetes mellitus. Postgraduate Medical Journal. 85, 1002 (Apr. 2009), 219–222. DOI:https://doi.org/10.1136/pgmj.2008.073379.

[27]

Daly, H. et al. 2015. Development of a self-management education module for those with type 2 diabetes on injectable therapies. Practical Diabetes. 32, 8 (Oct. 2015), 305–310a. DOI:https://doi.org/10.1002/pdi.1979.

[28]

Davies, M. et al. 2005. Improvement of Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes: Comparison of two treatment algorithms using insulin glargine. Diabetes Care. 28, 6 (Jun. 2005), 1282–1288. DOI:https://doi.org/10.2337/diacare.28.6.1282.

[29]

Davies, M. et al. 2005. Improvement of Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes: Comparison of two treatment algorithms using insulin glargine. Diabetes Care. 28, 6 (Jun. 2005), 1282–1288. DOI:https://doi.org/10.2337/diacare.28.6.1282.

[30]

Davies, M.J. et al. 2014. Efficacy and safety of insulin degludec given as part of basal-bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomized, open-label, treat-to-target non-inferiority trial. Diabetes, Obesity and Metabolism. 16, 10 (Oct. 2014), 922–930. DOI:https://doi.org/10.1111/dom.12298.

[31]

Davies, M.J. et al. 2009. Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study. Diabetes, Obesity and Metabolism. 11, 12 (Dec. 2009), 1153–1162. DOI:https://doi.org/10.1111/j.1463-1326.2009.01154.x.

[32]

Davies, M.J. et al. 2017. Impact of baseline HbA1c, diabetes duration and BMI on clinical outcomes in the LixiLan-O trial testing iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) versus insulin glargine and lixisenatide monocomponents. Diabetes, Obesity and Metabolism. (Apr. 2017). DOI:https://doi.org/10.1111/dom.12980.

[33]

Davies, M.J. and Chatterjee, S. 2017. Trial watch: Insulin initiation for type 2 diabetes mellitus in primary care. Nature Reviews Endocrinology. 13, 6 (Apr. 2017), 317–318. DOI:https://doi.org/10.1038/nrendo.2017.41.

[34]

Diabetes & Metabolism - Présentation - EM consulte: http://www.em-consulte.com/article/80031/alertePM#N1010C.

[35]

Diamant, M. et al. 2010. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. The Lancet. 375, 9733 (Jun. 2010), 2234–2243. DOI:https://doi.org/10.1016/S0140-6736(10)60406-0.

[36]

EASD Virtual Meeting: http://www.easdvirtualmeeting.org/resources/systematic-review-and-meta-analysis-of-the-efficacy-and-safety-of-sglt2-inhibitors-in-patients-with-type-2-diabetes-mellitus.

[37]

Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes - ClinicalKey: https://www-clinicalkey-com.ezproxy4.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858714701743.

[38]

Eng, C. et al. 2014. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. The Lancet. 384, 9961 (Dec. 2014), 2228–2234. DOI:https://doi.org/10.1016/S0140-6736(14)61335-0.

[39]

Evans, M. et al. 2011. A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations. Diabetes, Obesity and Metabolism. 13, 8 (Aug. 2011), 677–684. DOI:https://doi.org/10.1111/j.1463-1326.2011.01395.x.

[40]

F Game 2012. Annals of The Royal College of Surgeons of England. 94, 5 (2012). DOI:https://doi.org/doi:  10.1308/003588412X13171221591655.

[41]

Fineman, M.S. et al. 2012. GLP-1 based therapies: differential effects on fasting and postprandial glucose. Diabetes, Obesity and Metabolism. 14, 8 (Aug. 2012), 675–688. DOI:https://doi.org/10.1111/j.1463-1326.2012.01560.x.

[42]

Frandsen, C.S.S. and Madsbad, S. 2014. Efficacy and safety of dipeptidyl peptidase-4 inhibitors as an add-on to insulin treatment in patients with Type 2 diabetes: a review. Diabetic Medicine. 31, 11 (Nov. 2014), 1293–1300. DOI:https://doi.org/10.1111/dme.12561.

[43]

Frandsen, C.S.S. and Madsbad, S. 2014. Efficacy and safety of dipeptidyl peptidase-4 inhibitors as an add-on to insulin treatment in patients with Type 2 diabetes: a review. Diabetic Medicine. 31, 11 (Nov. 2014), 1293–1300. DOI:https://doi.org/10.1111/dme.12561.

[44]

Frisch, A. et al. 2010. Prevalence and Clinical Outcome of Hyperglycemia in the Perioperative Period in Noncardiac Surgery. Diabetes Care. 33, 8 (Aug. 2010), 1783–1788. DOI:https://doi.org/10.2337/dc10-0304.

[45]

Fullerton, B. et al. 1996. Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd.

[46]

Garber, A.J. et al. 2006. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes, Obesity and Metabolism. 8, 1 (Jan. 2006), 58–66. DOI:https://doi.org/10.1111/j.1463-1326.2005.00563.x.

[47]

Garber, A.J. et al. 2007. Premixed insulin treatment for type 2 diabetes: analogue or human? Diabetes, Obesity and Metabolism. 9, 5 (Sep. 2007), 630–639. DOI:https://doi.org/10.1111/j.1463-1326.2006.00654.x.

[48]

Giugliano, D. et al. 2011. Efficacy of Insulin Analogs in Achieving the Hemoglobin A1c Target of <7% in Type 2 Diabetes: Meta-analysis of randomized controlled trials. Diabetes Care. 34, 2 (Feb. 2011), 510–517. DOI:https://doi.org/10.2337/dc10-1710.

[49]

Goudswaard, A.N. et al. 1996. Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd.

[50]

Gough, S.C.L. et al. 2013. Low-Volume Insulin Degludec 200 Units/mL Once Daily Improves Glycemic Control Similarly to Insulin Glargine With a Low Risk of Hypoglycemia in Insulin-Naive Patients With Type 2 Diabetes: A 26-week, randomized, controlled, multinational, treat-to-target trial: The BEGIN LOW VOLUME trial. Diabetes Care. 36, 9 (Sep. 2013), 2536–2542. DOI:https://doi.org/10.2337/dc12-2329.

[51]

Gregory T. Mucha,Stacia Merkel,William Thomas,John P. Bantle Fasting and insulin glargine in individuals with type 1 diabetes. Diabetes Care.

[52]

Guevara-Aguirre, J. et al. 2004. Beneficial Effects of Addition of Oral Spray Insulin (Oralin) on Insulin Secretion and Metabolic Control in Subjects with Type 2 Diabetes Mellitus Suboptimally Controlled on Oral Hypoglycemic Agents. Diabetes Technology & Therapeutics. 6, 1 (Feb. 2004), 1–8. DOI:https://doi.org/10.1089/152091504322783341.

[53]

Gururaj Setty, S. et al. 2016. New insulins and newer insulin regimens: a review of their role in improving glycaemic control in patients with diabetes. Postgraduate Medical Journal. 92, 1085 (Mar. 2016), 152–164. DOI:https://doi.org/10.1136/postgradmedj-2015-133716.

[54]

Gurwitz, J.H. 1994. Glucocorticoids and the Risk for Initiation of Hypoglycemic Therapy. Archives of Internal Medicine. 154, 1 (Jan. 1994). DOI:https://doi.org/10.1001/archinte.1994.00420010131015.

[55]

Hannele Yki-Järvinen 2013. Is There Evidence to Support Use of Premixed or Prandial Insulin Regimens in Insulin-Naive or Previously Insulin-Treated Type 2 Diabetic Patients? Diabetes Care. 36, Suppl 2 (2013). DOI:https://doi.org/doi:  10.2337/dcS13-2026.

[56]

Hannele Yki-Jarvinen,Leena Juurinen,Michael Alvarsson,Tord Bystedt,Ian Caldwell,Melanie Davies Initiate insulin by aggressive titration and education (Initiate): randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups. Diabetes Care.

[57]

Heller, S. et al. 2012. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. The Lancet. 379, 9825 (Apr. 2012), 1489–1497. DOI:https://doi.org/10.1016/S0140-6736(12)60204-9.

[58]

Heller, S.R. et al. 2004. Hypoglycaemia with insulin aspart: a double-blind, randomised, crossover trial in subjects with Type 1 diabetes. Diabetic Medicine. 21, 7 (Jul. 2004), 769–775. DOI:https://doi.org/10.1111/j.1464-5491.2004.01244.x.

[59]

Hermansen, K. et al. 2006. A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naive People With Type 2 Diabetes. Diabetes Care. 29, 6 (Jun. 2006), 1269–1274. DOI:https://doi.org/10.2337/dc05-1365.

[60]

Hermansen, K. and Davies, M. 2007. Does insulin detemir have a role in reducing risk of insulin-associated weight gain? Diabetes, Obesity and Metabolism. 9, 3 (May 2007), 209–217. DOI:https://doi.org/10.1111/j.1463-1326.2006.00665.x.

[61]

Hirsch, I.B. et al. 2014. Options for prandial glucose management in type 2 diabetes patients using basal insulin: addition of a short-acting GLP-1 analogue versus progression to basal-bolus therapy. Diabetes, Obesity and Metabolism. 16, 3 (Mar. 2014), 206–214. DOI:https://doi.org/10.1111/dom.12136.

[62]

Hirsch, I.B. et al. 2017. Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with Type 1 diabetes: 1-year results from a randomized clinical trial (BOOST                              T1). Diabetic Medicine. 34, 2 (Feb. 2017), 167–173. DOI:https://doi.org/10.1111/dme.13068.

[63]

Holman, R.R. et al. 2008. 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. New England Journal of Medicine. 359, 15 (Oct. 2008), 1577–1589. DOI:https://doi.org/10.1056/NEJMoa0806470.

[64]

Holman, R.R. et al. 2007. Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes. New England Journal of Medicine. 357, 17 (Oct. 2007), 1716–1730. DOI:https://doi.org/10.1056/NEJMoa075392.

[65]

Holman, R.R. et al. 2007. Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes. New England Journal of Medicine. 357, 17 (Oct. 2007), 1716–1730. DOI:https://doi.org/10.1056/NEJMoa075392.

[66]

Holman, R.R. et al. 2009. Three-Year Efficacy of Complex Insulin Regimens in Type 2 Diabetes. New England Journal of Medicine. 361, 18 (Oct. 2009), 1736–1747. DOI:https://doi.org/10.1056/NEJMoa0905479.

[67]

Holman, R.R. et al. 2009. Three-Year Efficacy of Complex Insulin Regimens in Type 2 Diabetes. New England Journal of Medicine. 361, 18 (Oct. 2009), 1736–1747. DOI:https://doi.org/10.1056/NEJMoa0905479.

[68]

Holman, R.R. et al. 2009. Three-Year Efficacy of Complex Insulin Regimens in Type 2 Diabetes. New England Journal of Medicine. 361, 18 (Oct. 2009), 1736–1747. DOI:https://doi.org/10.1056/NEJMoa0905479.

[69]

Holman, R.R. and Turner, R.C. 1985. A Practical Guide to Basal and Prandial Insulin Therapy. Diabetic Medicine. 2, 1 (Jan. 1985), 45–53. DOI:https://doi.org/10.1111/j.1464-5491.1985.tb00592.x.

[70]

Holt, R.I.G. et al. 2016. Textbook of Diabetes. John Wiley & Sons, Incorporated.

[71]

Holt, R.I.G. 2010. Textbook of diabetes. Wiley-Blackwell.

[72]

Holt, R.I.G. et al. 2016. Textbook of Diabetes. John Wiley & Sons, Incorporated.

[73]

Holt, R.I.G. 2010. Textbook of diabetes. Wiley-Blackwell.

[74]

Home, P. et al. 2014. Insulin Therapy in People With Type 2 Diabetes: Opportunities and Challenges? Diabetes Care. 37, 6 (Jun. 2014), 1499–1508. DOI:https://doi.org/10.2337/dc13-2743.

[75]

Home, P.D. et al. 2015. New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4). Diabetes Care. 38, 12 (Dec. 2015), 2217–2225. DOI:https://doi.org/10.2337/dc15-0249.

[76]

Home, P.D. 2012. The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences. Diabetes, Obesity and Metabolism. 14, 9 (Sep. 2012), 780–788. DOI:https://doi.org/10.1111/j.1463-1326.2012.01580.x.

[77]

Hommel, I. et al. 2015. Perioperative diabetes care: room for improving the person centredness. Diabetic Medicine. 32, 4 (Apr. 2015), 561–568. DOI:https://doi.org/10.1111/dme.12600.

[78]

Horvath, K. et al. 1996. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd.

[79]

Horvath, K. et al. 1996. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd.

[80]

Hui, E. et al. 2010. Comparison of Humalog Mix 50 with human insulin Mix 30 in type 2 diabetes patients during Ramadan. International Journal of Clinical Practice. 64, 8 (Mar. 2010), 1095–1099. DOI:https://doi.org/10.1111/j.1742-1241.2010.02347.x.

[81]

Hui, E. et al. 2010. Comparison of Humalog Mix 50 with human insulin Mix 30 in type 2 diabetes patients during Ramadan. International Journal of Clinical Practice. 64, 8 (Mar. 2010), 1095–1099. DOI:https://doi.org/10.1111/j.1742-1241.2010.02347.x.

[82]

Hwang, J.L. and Weiss, R.E. 2014. Steroid-induced diabetes: a clinical and molecular approach to understanding and treatment. Diabetes/Metabolism Research and Reviews. 30, 2 (Feb. 2014), 96–102. DOI:https://doi.org/10.1002/dmrr.2486.

[83]

Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study: http://link.springer.com.ezproxy4.lib.le.ac.uk/article/10.1007/s00125-005-0132-0/fulltext.html.

[84]

Insulin treatment and the problem of weight gain in type 2 diabetes. - PubMed - NCBI: http://www.ncbi.nlm.nih.gov/pubmed/17102158.

[85]

Intensity of peri-operative glycemic control and postoperative outcomes in patients with diabetes: a meta-analysis - ClinicalKey: https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S0168822713001873.

[86]

Ismail-Beigi, F. 2012. Glycemic Management of Type 2 Diabetes Mellitus. New England Journal of Medicine. 366, 14 (Apr. 2012), 1319–1327. DOI:https://doi.org/10.1056/NEJMcp1013127.

[87]

Jackson, M.J. et al. 2016. Perioperative management of diabetes in elective patients: a region-wide audit. British Journal of Anaesthesia. 116, 4 (Apr. 2016), 501–506. DOI:https://doi.org/10.1093/bja/aev554.

[88]

Jenkins, K. 2014. II. Needle phobia: a psychological perspective. British Journal of Anaesthesia. 113, 1 (Jul. 2014), 4–6. DOI:https://doi.org/10.1093/bja/aeu013.

[89]

June James End-of-life care: Anything but a pathway.

[90]

June James Safety and insulin: implementation of national guidance at a local level. Journal of Diabetes Nursing.

[91]

Kahler, P. et al. 2014. Targeting intensive versus conventional glycaemic control for type 1 diabetes mellitus: a systematic review with meta-analyses and trial sequential analyses of randomised clinical trials. BMJ Open. 4, 8 (Aug. 2014), e004806–e004806. DOI:https://doi.org/10.1136/bmjopen-2014-004806.

[92]

Khedkar, A. et al. 2010. A dose range finding study of novel oral insulin (IN-105) under fed conditions in type 2 diabetes mellitus subjects. Diabetes, Obesity and Metabolism. 12, 8 (Feb. 2010), 659–664. DOI:https://doi.org/10.1111/j.1463-1326.2010.01213.x.

[93]

Kramer, C.K. et al. 2013. Short-term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and meta-analysis. The Lancet Diabetes & Endocrinology. 1, 1 (Sep. 2013), 28–34. DOI:https://doi.org/10.1016/S2213-8587(13)70006-8.

[94]

Kuhlmann, M. and Marre, M. 2010. Lessons learned from biosimilar epoetins and insulins. The British Journal of Diabetes & Vascular Disease. 10, 2 (Mar. 2010), 90–97. DOI:https://doi.org/10.1177/1474651409355454.

[95]

Kutz, A. et al. 2017. The association of admission hyperglycaemia and adverse clinical outcome in medical emergencies: the multinational, prospective, observational TRIAGE study. Diabetic Medicine. (Feb. 2017). DOI:https://doi.org/10.1111/dme.13325.

[96]

L. Luzi 1989. Effect of loss of first-phase insulin secretion on hepatic glucose production and tissue glucose disposal in humans. American Journal of Physiology - Endocrinology and Metabolism. 257, 2 (Aug. 1989), E241–E246.

[97]

Lambert, K. and Holt, R.I.G. 2013. The use of insulin analogues in pregnancy. Diabetes, Obesity and Metabolism. 15, 10 (Oct. 2013), 888–900. DOI:https://doi.org/10.1111/dom.12098.

[98]

Lankisch, M.R. et al. 2008. Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs. Diabetes, Obesity and Metabolism. (Sep. 2008). DOI:https://doi.org/10.1111/j.1463-1326.2008.00967.x.

[99]

Lasserson, D.S. et al. 2009. Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses. Diabetologia. 52, 10 (Oct. 2009), 1990–2000. DOI:https://doi.org/10.1007/s00125-009-1468-7.

[100]

Lasserson, D.S. et al. 2009. Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses. Diabetologia. 52, 10 (Oct. 2009), 1990–2000. DOI:https://doi.org/10.1007/s00125-009-1468-7.

[101]

Lea, Mary R.      Creme, Phyllis 2008. Writing At University. McGraw-Hill Education.

[102]

Levy, N. et al. 2016. Perioperative management of diabetes and the emerging role of anaesthetists as perioperative physicians. British Journal of Anaesthesia. 116, 4 (Apr. 2016), 443–447. DOI:https://doi.org/10.1093/bja/aew049.

[103]

Liu, D. et al. 2013. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy, Asthma & Clinical Immunology. 9, 1 (2013). DOI:https://doi.org/10.1186/1710-1492-9-30.

[104]

Luc JC van Loon 2000. Plasma insulin responses after ingestion of different amino acid or protein mixtures with carbohydrate. The American Journal of Clinical Nutrition. 72, 1 (Jan. 2000), 96–105.

[105]

Luzio, S.D. et al. 2010. The glucose lowering effect of an oral insulin (Capsulin) during an isoglycaemic clamp study in persons with type 2 diabetes. Diabetes, Obesity and Metabolism. 12, 1 (Jan. 2010), 82–87. DOI:https://doi.org/10.1111/j.1463-1326.2009.01146.x.

[106]

Manju Chandran,Steven V. Edelman Have insulin, will fly: diabetes management during air travel and time zone adjustment strategies. (Practical Pointers). Clinical Diabetes.

[107]

Martha M. Funnell Overcoming barriers to the initiation of insulin therapy. Clinical Diabetes.

[108]

Matthew C. Riddle,Julio Rosenstock,John Gerich The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care.

[109]

Mattoo, V. et al. 2003. A comparison of insulin lispro Mix25^TM and human insulin 30/70 in the treatment of type 2 diabetes during Ramadan. Diabetes Research and Clinical Practice. 59, 2 (Feb. 2003), 137–143. DOI:https://doi.org/10.1016/S0168-8227(02)00202-4.

[110]

McBain, H. et al. 2017. Barriers to and enablers of insulin self-titration in adults with Type 2 diabetes: a qualitative study. Diabetic Medicine. 34, 2 (Feb. 2017), 253–261. DOI:https://doi.org/10.1111/dme.13196.

[111]

McCrimmon, R.J. 2017. Old habits are hard to break: lessons from the study of hypoglycaemia. Diabetic Medicine. 34, 2 (Feb. 2017), 148–155. DOI:https://doi.org/10.1111/dme.13277.

[112]

Menting, J.G. et al. 2013. How insulin engages its primary binding site on the insulin receptor. Nature. 493, 7431 (Jan. 2013), 241–245. DOI:https://doi.org/10.1038/nature11781.

[113]

Mollema, E.D. et al. 2001. Phobia of self-injecting and self-testing in insulin-treated diabetes patients: opportunities for screening. Diabetic Medicine. 18, 8 (Dec. 2001), 671–674. DOI:https://doi.org/10.1046/j.1464-5491.2001.00547.x.

[114]

Morçöl, T. et al. 2004. Calcium phosphate-PEG-insulin-casein (CAPIC) particles as oral delivery systems for insulin. International Journal of Pharmaceutics. 277, 1–2 (Jun. 2004), 91–97. DOI:https://doi.org/10.1016/j.ijpharm.2003.07.015.

[115]

Nathan, D.M. et al. 2006. Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 29, 8 (Aug. 2006), 1963–1972. DOI:https://doi.org/10.2337/dc06-9912.

[116]

Nathan, D.M. 2014. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Overview. Diabetes Care. 37, 1 (Jan. 2014), 9–16. DOI:https://doi.org/10.2337/dc13-2112.

[117]

Nauck, M. 2016. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes, Obesity and Metabolism. 18, 3 (Mar. 2016), 203–216. DOI:https://doi.org/10.1111/dom.12591.

[118]

New IDegLira data show rapid and predictable glycaemic improvements in people with type 2 diabetes: http://www.multivu.com/players/English/72762519-novo-nordisk-IDegLira-treatment/.

[119]

New Insulin Glargine 300 U/mL: Glycemic Control and Hypoglycemia in a Meta-Analysis of Phase 3a EDITION Clinical Trials in People with T2DM - ClinicalKey: https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S1499267114003086.

[120]

Owens, D.R. et al. 2011. Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month ‘proof-of-concept’ study. Diabetes, Obesity and Metabolism. 13, 11 (Nov. 2011), 1020–1027. DOI:https://doi.org/10.1111/j.1463-1326.2011.01459.x.

[121]

Owens, D.R. 2013. Stepwise intensification of insulin therapy in Type 2 diabetes management-exploring the concept of the basal-plus approach in clinical practice. Diabetic Medicine. 30, 3 (Mar. 2013), 276–288. DOI:https://doi.org/10.1111/dme.12019.

[122]

P. Schneiter 1998. Kinetics of dexamethasone-induced alterations of glucose metabolism in healthy humans. American Journal of Physiology - Endocrinology and Metabolism. 275, 5 (Nov. 1998), E806–E813.

[123]

Park, S.W. et al. 2017. Insulin degludec/insulin aspart once daily in Type 2 diabetes: a comparison of simple or stepwise titration algorithms (BOOST                              : SIMPLE USE). Diabetic Medicine. 34, 2 (Feb. 2017), 174–179. DOI:https://doi.org/10.1111/dme.13069.

[124]

Peter Mansell The dose adjustment for normal eating (DAFNE) education programme. Journal of Diabetes Nursing.

[125]

Philip Raskin,Elsie Allen,Priscilla Hollander,Andrew Lewin,Robert A. Gabbay,Peter Hu Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care.

[126]

Pickup, J.C. et al. 2017. Glycemic Control During Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Insulin Injections in Type 2 Diabetes: Individual Patient Data Meta-analysis and Meta-regression of Randomized Controlled Trials. Diabetes Care. 40, 5 (May 2017), 715–722. DOI:https://doi.org/10.2337/dc16-2201.

[127]

Pozzilli, P. et al. 2005. Biokinetics of buccal spray insulin in patients with type 1 diabetes. Metabolism. 54, 7 (Jul. 2005), 930–934. DOI:https://doi.org/10.1016/j.metabol.2005.02.008.

[128]

Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial - ClinicalKey: https://www-clinicalkey-com.ezproxy4.lib.le.ac.uk/#!/content/journal/1-s2.0-S0140673610606320.

[129]

Raccah, D. et al. 2017. Review of basal-plus insulin regimen options for simpler insulin intensification in people with Type 2 diabetes mellitus. Diabetic Medicine. (Jun. 2017). DOI:https://doi.org/10.1111/dme.13390.

[130]

Raccah, D. et al. 2017. Review of basal-plus insulin regimen options for simpler insulin intensification in people with Type 2 diabetes mellitus. Diabetic Medicine. (Jun. 2017). DOI:https://doi.org/10.1111/dme.13390.

[131]

Raccah, D. et al. 2017. Review of basal-plus insulin regimen options for simpler insulin intensification in people with Type 2 diabetes mellitus. Diabetic Medicine. 34, 9 (Sep. 2017), 1193–1204. DOI:https://doi.org/10.1111/dme.13390.

[132]

Raccah, D. et al. 2017. Review of basal-plus insulin regimen options for simpler insulin intensification in people with Type 2 diabetes mellitus. Diabetic Medicine. 34, 9 (Sep. 2017), 1193–1204. DOI:https://doi.org/10.1111/dme.13390.

[133]

Randomized controlled trial of insulin detemir versus NPH for the treatment of pregnant women with diabetes - ClinicalKey: https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S0002937815005931.

[134]

Richter, B. and Neises, G. 1996. ‘Human’ insulin versus animal insulin in people with diabetes mellitus. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd.

[135]

Riddle, M.C. et al. 2013. Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: A 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care. 36, 9 (Sep. 2013), 2489–2496. DOI:https://doi.org/10.2337/dc12-2454.

[136]

Riddle, M.C. et al. 2014. New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1). Diabetes Care. 37, 10 (Oct. 2014), 2755–2762. DOI:https://doi.org/10.2337/dc14-0991.

[137]

Riddle, M.C. et al. 2014. Randomized, 1-year comparison of three ways to initiate and advance insulin for type 2 diabetes: twice-daily premixed insulin versus basal insulin with either basal-plus one prandial insulin or basal-bolus up to three prandial injections. Diabetes, Obesity and Metabolism. 16, 5 (May 2014), 396–402. DOI:https://doi.org/10.1111/dom.12225.

[138]

Rodbard, H.W. et al. 2017. Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naïve people with Type 2 diabetes: the DUAL IV trial. Diabetic Medicine. 34, 2 (Feb. 2017), 189–196. DOI:https://doi.org/10.1111/dme.13256.

[139]

Rorsman, P. and Renstr�m, E. 2003. Insulin granule dynamics in pancreatic beta cells. Diabetologia. 46, 8 (Aug. 2003), 1029–1045. DOI:https://doi.org/10.1007/s00125-003-1153-1.

[140]

Rosenstock, J. et al. 2013. Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 Diabetes: A randomized, crossover study. Diabetes Care. 36, 3 (Mar. 2013), 522–528. DOI:https://doi.org/10.2337/dc12-0067.

[141]

Rosenstock, J. et al. 2013. Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X). Diabetes Care. 36, 10 (Oct. 2013), 2945–2951. DOI:https://doi.org/10.2337/dc12-2709.

[142]

Rosenstock, J. et al. 2014. Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes. Diabetes Care. 37, 7 (Jul. 2014), 1815–1823. DOI:https://doi.org/10.2337/dc13-3055.

[143]

Rosenstock, J. et al. 2014. Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes. Diabetes Care. 37, 7 (Jul. 2014), 1815–1823. DOI:https://doi.org/10.2337/dc13-3055.

[144]

Rowles, S. et al. 2011. ABCD position statement on diabetes and end of life care. Practical Diabetes International. 28, 1 (Jan. 2011), 26–27. DOI:https://doi.org/10.1002/pdi.1547.

[145]

Rowles, S. et al. 2011. ABCD position statement on diabetes and end of life care. Practical Diabetes International. 28, 1 (Jan. 2011), 26–27. DOI:https://doi.org/10.1002/pdi.1547.

[146]

Russell-Jones, D. and Khan, R. 2007. Insulin-associated weight gain in diabetes – causes, effects and coping strategies. Diabetes, Obesity and Metabolism. 9, 6 (Nov. 2007), 799–812. DOI:https://doi.org/10.1111/j.1463-1326.2006.00686.x.

[147]

Shosuke Satake,Mary Courtney Moore,Kayano Igawa,Margaret Converse,Benjamin Farmer,Doss W. Neal Direct and indirect effects of insulin on glucose uptake and storage by the liver. (Original Articles). Diabetes.

[148]

Simmons, J.H. et al. 2007. Reliability of the Diabetes Fear of Injecting and Self-Testing Questionnaire in Pediatric Patients With Type 1 Diabetes. Diabetes Care. 30, 4 (Apr. 2007), 987–988. DOI:https://doi.org/10.2337/dc06-1553.

[149]

Simmons, L.R. et al. 2012. Steroid-Induced Diabetes: Is It Just Unmasking of Type 2 Diabetes? ISRN Endocrinology. 2012, (2012), 1–5. DOI:https://doi.org/10.5402/2012/910905.

[150]

Srinivasan, B.T. et al. 2008. Recent advances in the management of type 2 diabetes mellitus: a review. Postgraduate Medical Journal. 84, 996 (Oct. 2008), 524–531. DOI:https://doi.org/10.1136/pgmj.2008.067918.

[151]

Srinivasan, B.T. and Davies, M. 2014. Glycaemic management of type 2 diabetes. Medicine. 42, 12 (Dec. 2014), 711–717. DOI:https://doi.org/10.1016/j.mpmed.2014.09.011.

[152]

Suggested insulin regimens for patients with type 1 diabetes mellitus who wish to fast during the month of Ramadan - ClinicalKey: https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S0149291808002737.

[153]

Swinnen, S.G. et al. 1996. Insulin detemir versus insulin glargine for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd.

[154]

Tapley, M. and Needham, E. 2012. Improving end of life care for people with diabetes. Practical Diabetes. 29, 8 (Oct. 2012), 306–307a. DOI:https://doi.org/10.1002/pdi.1711.

[155]

Tikkanen-Dolenc, H. et al. 2016. Frequent and intensive physical activity reduces risk of cardiovascular events in type 1 diabetes. Diabetologia. (Dec. 2016). DOI:https://doi.org/10.1007/s00125-016-4189-8.

[156]

Villani, M. et al. 2017. Emergency treatment of hypoglycaemia: a guideline and evidence review. Diabetic Medicine. 34, 9 (Sep. 2017), 1205–1211. DOI:https://doi.org/10.1111/dme.13379.

[157]

W. Blair Geho 2014. A Single-blind, Placebo-controlled, Dose-ranging Trial of Oral Hepatic-directed Vesicle Insulin Add-on to Oral Antidiabetic Treatment in Patients With Type 2 Diabetes Mellitus. Journal of Diabetes Science and Technology. 8, 3 (2014). DOI:https://doi.org/doi:  10.1177/1932296814524871.

[158]

Wahren, J. and Kallas, A. 2012. Loss of Pulsatile Insulin Secretion: A Factor in the Pathogenesis of Type 2 Diabetes? Diabetes. 61, 9 (Sep. 2012), 2228–2229. DOI:https://doi.org/10.2337/db12-0664.

[159]

Walker, R.A. et al. 2010. Diabetes: a practical guide to managing your health. Dorling Kindersley.

[160]

Wang, C. et al. 2015. Biphasic vs basal bolus insulin regimen in Type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetic Medicine. 32, 5 (May 2015), 585–594. DOI:https://doi.org/10.1111/dme.12694.

[161]

Wang, W. et al. 2017. Effects of Insulin Plus Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in Treating Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Diabetes Therapy. (Jun. 2017). DOI:https://doi.org/10.1007/s13300-017-0282-3.

[162]

Yki-Jarvinen, H. et al. 2007. Initiate Insulin by Aggressive Titration and Education (INITIATE): A randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups. Diabetes Care. 30, 6 (Jun. 2007), 1364–1369. DOI:https://doi.org/10.2337/dc06-1357.

[163]

Yki-Jarvinen, H. and Kotronen, A. 2013. Is There Evidence to Support Use of Premixed or Prandial Insulin Regimens in Insulin-Naive or Previously Insulin-Treated Type 2 Diabetic Patients? Diabetes Care. 36, Supplement_2 (Aug. 2013), S205–S211. DOI:https://doi.org/10.2337/dcS13-2026.

[164]

Young, L.A. and Buse, J.B. 2014. GLP-1 receptor agonists and basal insulin in type 2 diabetes. The Lancet. 384, 9961 (Dec. 2014), 2180–2181. DOI:https://doi.org/10.1016/S0140-6736(14)61409-4.

[165]

Zambanini, A. et al. 1999. Injection related anxiety in insulin-treated diabetes. Diabetes Research and Clinical Practice. 46, 3 (Dec. 1999), 239–246. DOI:https://doi.org/10.1016/S0168-8227(99)00099-6.

[166]

Zinman, B. et al. 2011. Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. The Lancet. 377, 9769 (Mar. 2011), 924–931. DOI:https://doi.org/10.1016/S0140-6736(10)62305-7.

[167]

2016. : Summary of Revisions. Diabetes Care. 39, Supplement 1 (Jan. 2016), S4–S5. DOI:https://doi.org/10.2337/dc16-S003.

[168]

2012. Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia. New England Journal of Medicine. 367, 4 (Jul. 2012), 319–328. DOI:https://doi.org/10.1056/NEJMoa1203858.

[169]

Clinical effectiveness and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes: systematic review and economic evaluation.

[170]

2008. Effects of Intensive Glucose Lowering in Type 2 Diabetes. New England Journal of Medicine. 358, 24 (Jun. 2008), 2545–2559. DOI:https://doi.org/10.1056/NEJMoa0802743.

[171]

Efficacy and Safety of Glucagon-like peptide-1 receptor agonists  in type 2 diabetes  Systematic review and mixed-treatment comparison analysis.

[172]

2008. Hyperglycemia and Adverse Pregnancy Outcomes. New England Journal of Medicine. 358, 19 (May 2008), 1991–2002. DOI:https://doi.org/10.1056/NEJMoa0707943.

[173]

4AD. Professor Kamlesh Khunti - Coding, Classification and Diagnosis of Diabetes.

[174]

1993. The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. New England Journal of Medicine. 329, 14 (Sep. 1993), 977–986. DOI:https://doi.org/10.1056/NEJM199309303291401.

[175]

2002. Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial. BMJ. 325, 7367 (Oct. 2002), 746–746. DOI:https://doi.org/10.1136/bmj.325.7367.746.